ASCO 2021

ASCO 2021 - American Society of Clinical Oncology Annual Meeting 2021

The annual ASCO meeting brings together oncology professionals from around the world to discuss the latest scientific findings and advances in cancer treatment. This year, the congress will take place in a virtual format – click here to learn more about the program.

 

Boehringer Ingelheim is dedicated to collaborating with the oncology community on a shared journey to deliver innovative treatments for patients with cancer. At the congress we will be presenting recent findings relating to some of our pipeline and approved compounds. More information is provided below.

8 publications
Friday, 4 June – Tuesday, 8 June 2021
Virtual format

Virtual exhibit

Click here to view our ASCO 2021 virtual exhibit.

Publications

Explore our latest clinical and pre-clinical data during the scientific program at ASCO 2021.  

Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumor Type
  • All tumor types
Poster Discussion
A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828* in patients (pts) with advanced solid tumors
Author(s): LoRusso et al.

Poster discussion is available on demand on the ASCO platform

e-Presentation
Tumor Type(s): solid tumors
Abstract Number: 3016
There are no publications which meet your criteria on this date
Posters
A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828* in patients (pts) with advanced solid tumors
Author(s): LoRusso et al.
Poster Presentation
Tumor Type(s): solid tumors
Presentation Number: 3016
Phase Ib study of BI 836880* (VEGF/Ang2 nanobody) plus ezabenlimab (BI 754091*; anti-PD-1 antibody) in patients (pts) with solid tumors
Author(s): Girard et al.
Poster Presentation
Tumor Type(s): solid tumors
Presentation Number: 2579
Platform trial of ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients (pts) with previously treated advanced solid tumors: combination with BI 836880*, a VEGF/Ang2-blocking nanobody
Author(s): Hussein et al.
Poster Presentation
Tumor Type(s): solid tumors
Presentation Number: 2582
Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063*, a selective SIRPα inhibitor: results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors
Author(s): Champiat et al.
Poster Presentation
Tumor Type(s): solid tumors
Presentation Number: 2623
A phase Ib study of xentuzumab* plus abemaciclib and fulvestrant in patients (pts) with advanced hormone receptor-positive (HR+), HER2-negative breast cancer (BC) with visceral or non-visceral disease
Author(s): Yee et al.
Poster Presentation
Tumor Type(s): breast cancer
Presentation Number: 1057
A phase I, open-label, dose-escalation trial of BI 764532*, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3
Author(s): Wermke et al.
Poster Presentation
Tumor Type(s): small cell lung cancer
Presentation Number: TPS8588
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: a real-world cohort study (UpSwinG)
Author(s): Miura et al.
Poster Presentation
Tumor Type(s): non-small cell lung cancer
Presentation Number: 9072
Second-line nintedanib** + docetaxel for patients with lung adenocarcinoma after failure on first-line immune checkpoint inhibitor combination therapy: initial efficacy and safety results from VARGADO Cohort C
Author(s): Grohé et al.
Poster Presentation
Tumor Type(s): lung adenocarcinoma
Presentation Number: 9033
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

 

*Pipeline compounds shown here are under preclinical and/or clinical investigation and have not been approved. Their safety and efficacy have not been established.
**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumor histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.

© 2021 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: May 2021